Key result
Abciximab did not improve 1-year mortality compared with placebo in patients with non-ST-elevation acute coronary syndrome.
Why the study?
Does abciximab reduce 1-year mortality in patients with NSTE-ACS who are not scheduled for early coronary intervention?
RCT (n=7,800)
Placebo-controlled
Randomized
Does abciximab reduce 1-year mortality in patients with NSTE-ACS who are not scheduled for early coronary intervention?
In patients with NSTE-ACS managed medically without early revascularization, abciximab does not improve 1-year survival and is associated with excess mortality in subgroups with negative troponin or elevated CRP.
Answers are grounded in this paper and cite their sources.
Abciximab confers no benefit in medically managed NSTE-ACS; leaves open optimal GP IIb/IIIa use in this population.
BACKGROUND: This study was designed to investigate long-term effects of the glycoprotein IIb/IIIa inhibitor abciximab in patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention. METHODS AND RESULTS: A total of 7800 patients were included with an acute coronary syndrome without ST elevation, documented by either elevated cardiac troponin or transient or persistent ST-segment depression. They were randomized to abciximab bolus and 24-hour infusion, abciximab bolus and 48-hour infusion, or matching placebo. The overall 1-year mortality rate was 8.3% (649 patients). One-year mortality was 7.8% in the placebo group and 8.2% in the 24-hour and 9.0% in the 48-hour abciximab infusion group. Compared with placebo, the hazard ratio for the 24-hour infusion of abciximab was 1.1 (95% CI 0.86 to 1.29), and for the 48-hour infusion, it was 1.2 (95% CI 0.95 to 1.41). The lack of benefit of abciximab was observed in every subgroup studied. Patients with negative troponin or elevated C-reactive protein had a higher mortality rate after treatment with abciximab for 48 hours than with placebo: 8.5% versus 5.8% in those with negative troponin (P=0.02), 16.3% versus 12.1% in those with elevated C-reactive protein (P=0.04). CONCLUSIONS: Compared with placebo, abciximab did not provide any survival benefit at 1 year in patients admitted with an acute coronary syndrome with ST depression and/or elevated troponin who were not scheduled to undergo early coronary revascularization. In subgroups of patients, in particular those with low cardiac troponin or elevated C-reactive protein, abciximab was associated with excess mortality.
No takes yet. Share an insight, caveat, or question.
Ottervanger et al. (2003) conducted an RCT in Acute coronary syndrome without ST elevation (n=7,800). Abciximab vs. Matching placebo was evaluated on 1-year mortality (HR 1.1, 95% CI 0.86-1.29). Abciximab did not improve 1-year mortality compared with placebo in patients with non-ST-elevation acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: